Scientists have got success with a new injection of HIV. Taking this injection once a year can reduce the risk of HIV ...

Data from a very early-phase trial shows that the drug is safe and remains in the body for up to 56 weeks. From two ...

Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...

Researchers here described how they were able to safely and ethically enroll adolescents in a landmark trial of a drug that ...

Merck's DOR/ISL met primary efficacy and safety goals in two Phase 3 HIV trials. Marketing applications are planned for ...

The United States’ shutdown of HIV/Aids funding may harm global Aids programmes irreparably, jeopardising millions of lives ...

Severe mpox and long-term sequelae such as severe scarring were more likely to occur among HIV-positive patients with detectable viral loads and low CD4 counts.

UCSF researchers are the first to confirm that this approach is effective for the patients who need it most. Patients who ...

Two more people have been potentially cured of HIV after receiving stem cell transplants to treat blood cancer or bone marrow ...

A team of pharmaceutical researchers at biopharma company Gilead Sciences has announced that a reformulation of its HIV ...

Incident HCV infection more than doubled among HIV-positive MSM with no history of injection drug use between 1995 and 2023.

Researchers from the HIV Prevention Trials Network (HPTN) have presented results from the HPTN 094 ("INTEGRA") study at the ...